Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

Scandinavian Journal of Urology

Volumn 50, Issue 6, 2016, Pages 413-419

  Kinnunen, Pete T T ^a   Murtola, Teemu J ^a,b   Talala, Kirsi ^c   Taari, Kimmo ^d   Tammela, Teuvo L J ^a,b   Auvinen, Anssi ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c FINNISH CANCER REGISTRY   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Anticoagulant drugs; cohort; metastasis; prostate cancer; risk; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXIDOREDUCTASE INHIBITOR; WARFARIN;

ADULT; AGED; ARTICLE; ATTRIBUTABLE RISK; CANCER GRADING; CANCER RISK; CANCER SCREENING; CANCER STAGING; FOLLOW UP; GLEASON SCORE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SHORT COURSE THERAPY; CONTROLLED STUDY; EARLY CANCER DIAGNOSIS; FINLAND; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME FACTOR;

AGED; ANTICOAGULANTS; EARLY DETECTION OF CANCER; FINLAND; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS; WARFARIN;

EID: 84987909476     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.1080/21681805.2016.1228085     Document Type: Article

References (34)

1. S.Schulman, P.Lindmarker Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000;342:1953–8.
2. J.A.Baron, G.Gridley, E.Weiderpass, O.Nyren, M.Linet Venous thromboembolism and cancer. Lancet 1998;351:1077–80.
3. A.K.Kakkar, F.Macbeth Antithrombotic therapy and survival in patients with malignant disease. Br J Cancer 2010;102:S24–9.
4. L.J.Gay, B.Felding-Habermann Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11:123–34.
5. E.M.Battinelli, B.A.Markens, R.A.Kulenthirarajan, K.R.Machlus, R.Flaumenhaft, J.E.ItalianoJr. Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood 2014;123:101–12.
6. J.S.Palumbo, K.W.Kombrinck, A.F.Drew, T.S.Grimes, J.H.Kiser, J.L.Degen,. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96:3302–9.
7. H.F.Dvorak, V.S.Harvey, P.Estrella, L.F.Brown, J.McDonagh, A.M.Dvorak Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 1987;57:673–86.
8. S.Schulman, A.S.Rhedin, P.Lindmarker, A.Carlsson, G.Larfars, P.Nicol,. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661–5.
9. M.R.Taliani, G.Agnelli, P.Prandoni, C.Becattini, M.Moia, M.Bazzan,. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost 2003;1:1730–3.
10. T.P.Ahern, L.Pedersen, C.Svaerke, K.J.Rothman, H.T.Sorensen, T.L.Lash The association between vitamin K antagonist therapy and site-specific cancer incidence estimated by using heart valve replacement as an instrumental variable. Am J Epidemiol 2011;174:1382–90.
11. V.Tagalakis, H.Tamim, M.Blostein, J.P.Collet, J.A.Hanley, S.R.Kahn Use of warfarin and risk of urogenital cancer:a population-based, nested case-control study. Lancet Oncol 2007;8:395–402.
12. V.Pengo, F.Noventa, G.Denas, M.F.Pengo, U.Gallo, A.M.Grion,. Long-term use of vitamin K antagonists and incidence of cancer:a population-based study. Blood 2011;117:1707–9.
13. A.Pottegård, S.Friis, J.Hallas Cancer risk in long-term users of vitamin K antagonists:a population-based case-control study. Int J Cancer 2013;132:2606–12.
14. V.Tagalakis, H.Tamim The effect of warfarin use on clinical stage and histological grade of prostate cancer. Pharmacoepidemiol Drug Saf 2010;19:436–9.
15. A.Blanc-Lapierre, D.Weiss, M.E.Parent Use of oral anticoagulants and risk of prostate cancer:a population-based case-control study in Montreal, Canada. Cancer Causes Control 2014;25:1159–66.
16. V.Bobek, J.Kovarik Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004;58:213–19.
17. S.M.Smorenburg, C.J.Van Noorden The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001;53:93–105.
18. J.H.Im, W.Fu, H.Wang, S.K.Bhatia, D.A.Hammer, M.A.Kowalska,. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 2004;64:8613–19.
19. T.P.Kilpeläinen, T.L.Tammela, N.Malila, M.Hakama, H.Santti, L.Määttänen,. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst 2013;105:719–25.
20. S.J.Freedland, R.J.Hamilton, L.Gerber, L.L.Banez, D.M.Moreira, G.L.Andriole,. Statin use and risk of prostate cancer and high-grade prostate cancer:results from the REDUCE study. Prostate Cancer Prostatic Dis 2013;16:254–9.
21. A.Hitron, V.Adams, J.Talbert, D.Steinke The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol 2012;36:e243–50.
22. K.J.Kemppainen, T.L.J.Tammela, A.Auvinen, T.J.Murtola The association between antihypertensive drug use and incidence of prostate cancer in Finland:a population-based case-control study. Cancer Causes Control 2011;22:1445–52.
23. Y.Liu, J.Chen, L.Xie, J.Wang, T.Li, Y.He,. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality:a systematic review and meta-analysis. BMC Med 2014;12:55.
24. S.M.Mahmud, E.L.Franco, A.G.Aprikian Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk:a meta-analysis. Int J Cancer 2010;127:1680–91.
25. R.M.Martin, L.Vatten, D.Gunnell, P.Romundstad Blood pressure and risk of prostate cancer:cohort Norway (CONOR). Cancer Causes Control 2010;21:463–72.
26. T.J.Murtola, T.L.J.Tammela, L.Maattanen, M.Hakama, A.Auvinen Prostate cancer risk among users of finasteride and alpha-blockers – a population based case-control study. Eur J Cancer 2007;43:775–81.
27. T.Nordstrom, M.Clements, R.Karlsson, J.Adolfsson, H.Gronberg The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. Eur J Cancer 2015;51:725–33.
28. M.A.Preston, K.M.Wilson, S.C.Markt, R.Ge, C.Morash, M.J.Stampfer,. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med 2014;174:1301–7.
29. D.Robinson, H.Garmo, A.Bill-Axelson, L.Mucci, L.Holmberg, P.Stattin. Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men:nationwide, population based case-control study. BMJ 2013;346:f3406.
30. A.C.Vidal, L.E.Howard, D.M.Moreira, R.Castro-Santamaria, G.L.Andriole, S.J.Freedland Aspirin, NSAIDs, and risk of prostate cancer:results from the REDUCE study. Clin Cancer Res 2015;21:756–62.
31. X.Wang, Y.Lin, J.Wu, Y.Zhu, X.L.Xu, X.Xu,. Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk. World J Surg Oncol 2014;12:304.
32. A.G.Renehan, M.Tyson, M.Egger, R.F.Heller, M.Zwahlen Body-mass index and incidence of cancer:a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569–78.
33. K.Bhaskaran, I.Douglas, H.Forbes, I.dos-Santos-Silva, D.A.Leon, L.Smeeth. Body-mass index and risk of 22 specific cancers:a population-based cohort study of 5·24 million UK adults. Lancet 2014;384:755–65.
34. F.Islami, D.M.Moreira, P.Boffetta, S.J.Freedland A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol 2014;66:1054–64.